On December 18, according to the official website of the U.S. Food and Drug Administration (FDA), Brian King, director of the FDA’s Center for Tobacco Products (CTP), issued a statement releasing the center’s comprehensive strategic plan.
Previously, CTP responded to the evaluation of an independent expert panel organized by the Reagan-Udall Foundation and announced that it has begun to formulate a new five-year strategic plan and will publish it before the end of the year. Since then, the Center has focused on the new strategic plan and actively incorporated feedback from external stakeholders during public comment periods and hearings to improve its planning capabilities.
The CTP's new strategic plan, which describes how the center will work and manage its staff over the next five years, was officially launched today. This strategic plan opens a new chapter for CTP, building on the solid foundation established since the center’s founding in 2009. Under the guidance of the plan, the work goal of CTP is to reduce the negative health effects caused by tobacco use, including ensuring the standardized operation of the market, preventing the public from starting to use tobacco products, encouraging users of tobacco products to quit smoking, and reducing the cost of tobacco product use. the harm caused.
In developing this strategic plan, CTP also updated its vision and mission to more accurately reflect the nature of its work and guide future activities. These changes to UTF highlight CTP’s public health focus and the importance of advancing health parity. This strategic plan of CTP stipulates five goals, ten results, and proposes a number of corresponding goals.
CTP will work together to achieve these goals and results by issuing high-impact regulations, applying scientific methods to review applications, implementing timely and impactful compliance and enforcement strategies, and educating the public about the risks of tobacco products.
